
Análisis exploratorio

Tamara Ricardo

2023-10-12

### Valores ausentes



### Descripción de la muestra

| **Characteristic** | **N = 661**1 |
| --- | --- |
| edad | 61 (51, 69) |
| edad\_cat |  |
| 0-19 | 4 (0.6%) |
| 20-39 | 52 (7.9%) |
| 40-59 | 250 (38%) |
| 60-79 | 314 (48%) |
| 80+ | 41 (6.2%) |
| sexo |  |
| Femenino | 378 (57%) |
| Masculino | 283 (43%) |
| comorb\_met |  |
| No | 315 (80%) |
| Si | 81 (20%) |
| comorb\_cvg |  |
| No | 260 (64%) |
| Si | 144 (36%) |
| comorb\_rin |  |
| No | 382 (98%) |
| Si | 8 (2.1%) |
| comorb\_res |  |
| No | 355 (91%) |
| Si | 35 (9.0%) |
| comorb\_neu |  |
| No | 382 (99%) |
| Si | 3 (0.8%) |
| comorb\_hiv |  |
| No | 372 (96%) |
| Si | 17 (4.4%) |
| comorb\_heb |  |
| No | 384 (99%) |
| Si | 4 (1.0%) |
| comorb\_hec |  |
| No | 387 (99%) |
| Si | 4 (1.0%) |
| comorb\_alc |  |
| No | 366 (95%) |
| Si | 21 (5.4%) |
| comorb\_hep |  |
| No | 384 (99%) |
| Si | 4 (1.0%) |
| comorb\_tab |  |
| No | 294 (74%) |
| Si | 102 (26%) |
| icd10\_cat\_1 |  |
| Leukemias and related conditions | 9 (1.4%) |
| Malignant neoplasms of bone and articular cartilage | 4 (0.6%) |
| Malignant neoplasms of breast | 137 (21%) |
| Malignant neoplasms of digestive organs | 150 (23%) |
| Malignant neoplasms of eye, brain and other parts of central nervous system | 18 (2.7%) |
| Malignant neoplasms of female genital organs | 91 (14%) |
| Malignant neoplasms of ill-defined, other secondary and unspecified sites | 62 (9.4%) |
| Malignant neoplasms of lip, oral cavity and pharynx | 19 (2.9%) |
| Malignant neoplasms of male genital organs | 20 (3.0%) |
| Malignant neoplasms of respiratory and intrathoracic organs | 83 (13%) |
| Malignant neoplasms of thyroid and other endocrine glands | 20 (3.0%) |
| Malignant neoplasms of urinary tract | 18 (2.7%) |
| Melanoma and other malignant neoplasms of skin | 28 (4.2%) |
| tipo\_CA\_1 |  |
| Hematológico | 24 (3.6%) |
| Sólido | 637 (96%) |
| evol\_CA\_1 |  |
| Distante | 60 (12%) |
| In Situ | 44 (8.9%) |
| Localizado | 213 (43%) |
| Regionalizado | 180 (36%) |
| ecog |  |
| 0 | 211 (40%) |
| 1 | 239 (45%) |
| 2 | 69 (13%) |
| 3 | 7 (1.3%) |
| gravedad\_CA |  |
| Grave | 242 (37%) |
| Leve | 419 (63%) |
| metastasis |  |
| No | 600 (91%) |
| Si | 61 (9.2%) |
| mas\_un\_tumor |  |
| No | 650 (98%) |
| Si | 11 (1.7%) |
| cat\_dx\_covid |  |
| NEG | 644 (97%) |
| POS | 17 (2.6%) |
| 1Median (IQR); n (%) | |

### Compara pacientes con y sin diagnóstico de COVID-19

| **Characteristic** | **NEG**, N = 6441 | **POS**, N = 171 | **p-value**2 |
| --- | --- | --- | --- |
| **edad** | 61 (51, 69) | 55 (42, 66) | 0.063 |
| **edad\_cat** |  |  | 0.15 |
| 0-19 | 4 (0.6%) | 0 (0%) |  |
| 20-39 | 49 (7.6%) | 3 (18%) |  |
| 40-59 | 241 (37%) | 9 (53%) |  |
| 60-79 | 310 (48%) | 4 (24%) |  |
| 80+ | 40 (6.2%) | 1 (5.9%) |  |
| **sexo** |  |  | 0.4 |
| Femenino | 370 (57%) | 8 (47%) |  |
| Masculino | 274 (43%) | 9 (53%) |  |
| **comorb\_met** |  |  | >0.9 |
| No | 304 (80%) | 11 (79%) |  |
| Si | 78 (20%) | 3 (21%) |  |
| **comorb\_cvg** |  |  | 0.8 |
| No | 250 (64%) | 10 (71%) |  |
| Si | 140 (36%) | 4 (29%) |  |
| **comorb\_rin** |  |  | >0.9 |
| No | 368 (98%) | 14 (100%) |  |
| Si | 8 (2.1%) | 0 (0%) |  |
| **comorb\_res** |  |  | >0.9 |
| No | 342 (91%) | 13 (93%) |  |
| Si | 34 (9.0%) | 1 (7.1%) |  |
| **comorb\_neu** |  |  | >0.9 |
| No | 368 (99%) | 14 (100%) |  |
| Si | 3 (0.8%) | 0 (0%) |  |
| **comorb\_hiv** |  |  | >0.9 |
| No | 358 (95%) | 14 (100%) |  |
| Si | 17 (4.5%) | 0 (0%) |  |
| **comorb\_heb** |  |  | **0.007** |
| No | 372 (99%) | 12 (86%) |  |
| Si | 2 (0.5%) | 2 (14%) |  |
| **comorb\_hec** |  |  | >0.9 |
| No | 373 (99%) | 14 (100%) |  |
| Si | 4 (1.1%) | 0 (0%) |  |
| **comorb\_alc** |  |  | 0.5 |
| No | 353 (95%) | 13 (93%) |  |
| Si | 20 (5.4%) | 1 (7.1%) |  |
| **comorb\_hep** |  |  | >0.9 |
| No | 370 (99%) | 14 (100%) |  |
| Si | 4 (1.1%) | 0 (0%) |  |
| **comorb\_tab** |  |  | 0.4 |
| No | 285 (75%) | 9 (64%) |  |
| Si | 97 (25%) | 5 (36%) |  |
| **tipo\_CA\_1** |  |  | 0.12 |
| Hematológico | 22 (3.4%) | 2 (12%) |  |
| Sólido | 622 (97%) | 15 (88%) |  |
| **evol\_CA\_1** |  |  | >0.9 |
| Distante | 58 (12%) | 2 (13%) |  |
| In Situ | 43 (8.9%) | 1 (6.7%) |  |
| Localizado | 206 (43%) | 7 (47%) |  |
| Regionalizado | 175 (36%) | 5 (33%) |  |
| **ecog** |  |  | 0.8 |
| 0 | 203 (40%) | 8 (50%) |  |
| 1 | 232 (45%) | 7 (44%) |  |
| 2 | 68 (13%) | 1 (6.3%) |  |
| 3 | 7 (1.4%) | 0 (0%) |  |
| **gravedad\_CA** |  |  | 0.7 |
| Grave | 235 (36%) | 7 (41%) |  |
| Leve | 409 (64%) | 10 (59%) |  |
| **metastasis** |  |  | 0.7 |
| No | 585 (91%) | 15 (88%) |  |
| Si | 59 (9.2%) | 2 (12%) |  |
| **mas\_un\_tumor** |  |  | >0.9 |
| No | 633 (98%) | 17 (100%) |  |
| Si | 11 (1.7%) | 0 (0%) |  |
| 1Median (IQR); n (%) | | | |
| 2Wilcoxon rank sum test; Fisher's exact test; Pearson's Chi-squared test | | | |

## Análisis datos para pacientes con datos completos (n = 321)

| **Characteristic** | **NEG**, N = 6441 | **POS**, N = 171 | **p-value**2 |
| --- | --- | --- | --- |
| **edad** | 61 (51, 69) | 55 (42, 66) | 0.063 |
| **edad\_cat** |  |  | 0.15 |
| 0-19 | 4 (0.6%) | 0 (0%) |  |
| 20-39 | 49 (7.6%) | 3 (18%) |  |
| 40-59 | 241 (37%) | 9 (53%) |  |
| 60-79 | 310 (48%) | 4 (24%) |  |
| 80+ | 40 (6.2%) | 1 (5.9%) |  |
| **sexo** |  |  | 0.4 |
| Femenino | 370 (57%) | 8 (47%) |  |
| Masculino | 274 (43%) | 9 (53%) |  |
| **comorb\_met** |  |  | >0.9 |
| No | 304 (80%) | 11 (79%) |  |
| Si | 78 (20%) | 3 (21%) |  |
| **comorb\_cvg** |  |  | 0.8 |
| No | 250 (64%) | 10 (71%) |  |
| Si | 140 (36%) | 4 (29%) |  |
| **comorb\_rin** |  |  | >0.9 |
| No | 368 (98%) | 14 (100%) |  |
| Si | 8 (2.1%) | 0 (0%) |  |
| **comorb\_res** |  |  | >0.9 |
| No | 342 (91%) | 13 (93%) |  |
| Si | 34 (9.0%) | 1 (7.1%) |  |
| **comorb\_neu** |  |  | >0.9 |
| No | 368 (99%) | 14 (100%) |  |
| Si | 3 (0.8%) | 0 (0%) |  |
| **comorb\_hiv** |  |  | >0.9 |
| No | 358 (95%) | 14 (100%) |  |
| Si | 17 (4.5%) | 0 (0%) |  |
| **comorb\_heb** |  |  | **0.007** |
| No | 372 (99%) | 12 (86%) |  |
| Si | 2 (0.5%) | 2 (14%) |  |
| **comorb\_hec** |  |  | >0.9 |
| No | 373 (99%) | 14 (100%) |  |
| Si | 4 (1.1%) | 0 (0%) |  |
| **comorb\_alc** |  |  | 0.5 |
| No | 353 (95%) | 13 (93%) |  |
| Si | 20 (5.4%) | 1 (7.1%) |  |
| **comorb\_hep** |  |  | >0.9 |
| No | 370 (99%) | 14 (100%) |  |
| Si | 4 (1.1%) | 0 (0%) |  |
| **comorb\_tab** |  |  | 0.4 |
| No | 285 (75%) | 9 (64%) |  |
| Si | 97 (25%) | 5 (36%) |  |
| **tipo\_CA\_1** |  |  | 0.12 |
| Hematológico | 22 (3.4%) | 2 (12%) |  |
| Sólido | 622 (97%) | 15 (88%) |  |
| **evol\_CA\_1** |  |  | >0.9 |
| Distante | 58 (12%) | 2 (13%) |  |
| In Situ | 43 (8.9%) | 1 (6.7%) |  |
| Localizado | 206 (43%) | 7 (47%) |  |
| Regionalizado | 175 (36%) | 5 (33%) |  |
| **ecog** |  |  | 0.8 |
| 0 | 203 (40%) | 8 (50%) |  |
| 1 | 232 (45%) | 7 (44%) |  |
| 2 | 68 (13%) | 1 (6.3%) |  |
| 3 | 7 (1.4%) | 0 (0%) |  |
| **gravedad\_CA** |  |  | 0.7 |
| Grave | 235 (36%) | 7 (41%) |  |
| Leve | 409 (64%) | 10 (59%) |  |
| **metastasis** |  |  | 0.7 |
| No | 585 (91%) | 15 (88%) |  |
| Si | 59 (9.2%) | 2 (12%) |  |
| **mas\_un\_tumor** |  |  | >0.9 |
| No | 633 (98%) | 17 (100%) |  |
| Si | 11 (1.7%) | 0 (0%) |  |
| 1Median (IQR); n (%) | | | |
| 2Wilcoxon rank sum test; Fisher's exact test; Pearson's Chi-squared test | | | |